The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard

References

1. 1.↵
   1. Rosen BR,
   2. Belliveau JW,
   3. Vevea JM,
   4. et al

   . Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–65

   PubMedWeb of Science
2. 2.↵
   1. Boxerman JL,
   2. Rosen BR,
   3. Weisskoff RM.

   . Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging 1997;7:528–37

   PubMed
3. 3.↵
   1. Donahue KM,
   2. Krouwer HG,
   3. Rand SD,
   4. et al

   . Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845–53

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Law M,
   2. Yang S,
   3. Babb JS,
   4. et al

   . Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25:746–55

   Abstract/FREE Full Text
5. 5.↵
   1. Spampinato MV,
   2. Smith JK,
   3. Kwock L,
   4. et al

   . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204–12

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Emblem KE,
   2. Scheie D,
   3. Due-Tonnessen P,
   4. et al

   . Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 2008;29:1664–70

   Abstract/FREE Full Text
7. 7.↵
   1. Morita N,
   2. Wang S,
   3. Chawla S,
   4. et al

   . Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging 2010; 32:803–08

   CrossRefPubMed
8. 8.↵
   1. Law M,
   2. Oh S,
   3. Johnson G,
   4. et al

   . Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099–107

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Hirai T,
   2. Murakami R,
   3. Nakamura H,
   4. et al

   . Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1505–10

   Abstract/FREE Full Text
10. 10.↵
    1. Law M,
    2. Young RJ,
    3. Babb JS,
    4. et al

    . Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Knopp EA,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–98

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Maia AC Jr.,
    2. Malheiros SM,
    3. da Rocha AJ,
    4. et al

    . Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 2004;101:970–76

    PubMed
13. 13.↵
    1. Ulmer S,
    2. Helle M,
    3. Jansen O,
    4. et al

    . Intraoperative dynamic susceptibility contrast weighted magnetic resonance imaging (iDSC-MRI): technical considerations and feasibility. Neuroimage 2009;45:38–43

    CrossRefPubMed
14. 14.↵
    1. Law M,
    2. Oh S,
    3. Babb JS,
    4. et al

    . Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 2006;238:658–67

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Danchaivijitr N,
    2. Waldman AD,
    3. Tozer DJ,
    4. et al

    . Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008;247:170–78

    CrossRefPubMed
16. 16.↵
    1. Cha S,
    2. Knopp EA,
    3. Johnson G,
    4. et al

    . Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881–90

    Abstract/FREE Full Text
17. 17.↵
    1. Essock-Burns E,
    2. Lupo JM,
    3. Cha S,
    4. et al

    . Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. J Neurooncol 2011;13:119–31
18. 18.↵
    1. Barajas RF Jr.,
    2. Chang JS,
    3. Segal MR,
    4. et al

    . Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486–96

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Hu LS,
    2. Baxter LC,
    3. Smith KA,
    4. et al

    . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from post-treatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58

    Abstract/FREE Full Text
20. 20.↵
    1. Gahramanov S,
    2. Raslan AM,
    3. Muldoon LL,
    4. et al

    . Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011;79:514–23

    CrossRefPubMed
21. 21.↵
    1. Schmainda KM,
    2. Rand SD,
    3. Joseph AM,
    4. et al

    . Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004;25:1524–32

    Abstract/FREE Full Text
22. 22.↵
    1. Boxerman JL,
    2. Schmainda KM,
    3. Weisskoff RM.

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67

    Abstract/FREE Full Text
23. 23.↵
    1. Quarles CC,
    2. Gochberg DF,
    3. Gore JC,
    4. et al

    . A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol 2009;54:5749–66

    CrossRefPubMed
24. 24.↵
    1. Paulson ES,
    2. Schmainda KM.

    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Bjornerud A,
    2. Sorensen AG,
    3. Mouridsen K,
    4. et al

    . T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI. Part I. Theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 2011;31:2041–53. Epub 2011 Apr 20

    CrossRefPubMed
26. 26.↵
    1. Aronen HJ,
    2. Pardo FS,
    3. Kennedy DN,
    4. et al

    . High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189–200

    Abstract/FREE Full Text
27. 27.↵
    1. Vonken EP,
    2. van Osch MJ,
    3. Bakker CJ,
    4. et al

    . Simultaneous quantitative cerebral perfusion and Gd-DTPA extravasation measurement with dual-echo dynamic susceptibility contrast MRI. Magn Reson Med 2000;43:820–27

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Uematsu H,
    2. Maeda M,
    3. Sadato N,
    4. et al

    . Blood volume of gliomas determined by double-echo dynamic perfusion-weighted MR imaging: a preliminary study. AJNR Am J Neuroradiol 2001;22:1915–19

    Abstract/FREE Full Text
29. 29.↵
    1. Wetzel SG,
    2. Cha S,
    3. Johnson G,
    4. et al

    . Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002;224:797–803

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Wong JC,
    2. Provenzale JM,
    3. Petrella JR.

    . Perfusion MR imaging of brain neoplasms. AJR Am J Roentgenol 2000;174:1147–57

    PubMed
31. 31.↵
    1. Weisskoff RM,
    2. Boxerman JL,
    3. Sorensen AG,
    4. et al

    . Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. In: Proceedings of the Second Meeting of the Society of Magnetic Resonance, San Francisco, California. August 6–12, 1994:279
32. 32.↵
    1. Johnson G,
    2. Wetzel SG,
    3. Cha S,
    4. et al

    . Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961–68

    CrossRefPubMed
33. 33.↵
    1. Quarles CC,
    2. Ward BD,
    3. Schmainda KM.

    . Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magn Reson Med 2005;53:1307–16

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Cox RW.

    . AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–73

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Simonsen CZ,
    2. Ostergaard L,
    3. Vestergaard-Poulsen P,
    4. et al

    . CBF and CBV measurements by USPIO bolus tracking: reproducibility and comparison with Gd-based values. J Magn Reson Imaging 1999;9:342–47

    CrossRefPubMed
36. 36.↵
    1. Hu LS,
    2. Baxter LC,
    3. Pinnaduwage DS,
    4. et al

    . Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010;31:40–48

    Abstract/FREE Full Text
37. 37.↵
    1. Mangla R,
    2. Kolar B,
    3. Zhu T,
    4. et al

    . Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR Am J Neuroradiol 2011;32:1004–10

    Abstract/FREE Full Text
38. 38.↵
    1. Cha S,
    2. Knopp EA,
    3. Johnson G,
    4. et al

    . Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Loubeyre P,
    2. De Jaegere T,
    3. Bosmans H,
    4. et al

    . Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla. J Magn Reson Imaging 1999;9:447–53

    CrossRefPubMed
40. 40.↵
    1. Enochs WS,
    2. Harsh G,
    3. Hochberg F,
    4. et al

    . Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228–32

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Neuwelt EA,
    2. Varallyay CG,
    3. Manninger S,
    4. et al

    . The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007;60:601–11

    PubMedWeb of Science
42. 42.↵
    1. Varallyay CG,
    2. Muldoon LL,
    3. Gahramanov S,
    4. et al

    . Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009;29:853–60

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Dosa E,
    2. Guillaume DJ,
    3. Haluska M,
    4. et al

    . Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. J Neurooncol 2011;13:251–60
44. 44.↵
    1. Zama A,
    2. Tamura M,
    3. Inoue HK.

    . Three-dimensional observations on microvascular growth in rat glioma using a vascular casting method. J Cancer Res Clin Oncol 1991;117:396–402

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Boxerman JL,
    2. Hamberg LM,
    3. Rosen BR,
    4. et al

    . MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–66

    CrossRefPubMedWeb of Science